检索结果-南通市图书馆

Effects of Shenqi Xiangyi granules in advanced gastric cancer chemotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第1期17卷 169-175页

作者： Xiao-Jing Shi Yu Song Xue-Xue Liang Ting Chen Huang-Yu Hao Xue Han Ya-Nan Chen department of oncology Zhangjiagang First People's HospitalSuzhou 215600Jiangsu ProvinceChina

BACKGROUND Owing to the absence of specific symptoms in early-stage gastric cancer,most patients are diagnosed at intermediate or advanced *** a result,treatment often shifts from surgery to other therapies,with chemotherapy and targeted therapies being the primary options for advanced gastric cancer treatment.A total of 116 patients with advanced gastric cancer,admitted from January 2021 to December 2023,were selected and divided into two groups of 58 each using the random number table *** control group received FOLFOX4 chemothe-rapy(oxaliplatin+calcium+folinate+5-fluorouracil)combined with intravenous *** observation group received the same treatment as the control group,supplemented by oral administration of Senqi Shiyiwei *** groups underwent treatment cycles of 3 weeks,with a minimum of two *** therapeutic efficacy,immune mechanisms,and treatment-related toxicity and side effects were compared between the *** objective remission rate in the observation group(55.17%)was higher than that of the control group(36.21%)(P0.05).CONCLUSION Adjuvant therapy with Shenqixian granules may enhance the efficacy of simudizumab combined with FOLFOX4 chemotherapy in advanced gastric cancer and the immune function by increasing immune cell counts,making it a valuable option in clinical treatment.

关键词： Sindilizumab FOLFOX4 chemotherapy Advanced gastric cancer Ginseng Qi Xiangyi granule Clinic treatment

Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第1期17卷 101-109页

作者： Mariarosaria D'Amato Gennaro Iengo Nicola Massa Chiara Carlomagno department of oncology Ospedale San Rocco ASL CasertaSessa Aurunca 81037CampaniaItaly department of Clinical Medicine and Surgery University of Naples Federico IINaples 80131CampaniaItaly

BACKGROUND Fluoropyrimidines are metabolized in the liver by the enzyme dihydropyrimidine dehydrogenase(DPD),encoded by the DPYD *** 7%of the European population is a carrier of DPYD gene polymorphisms associated with reduced DPD enzyme *** To assess the prevalence of DPYD polymorphisms and their impact on fluoropyrimidine tolerability in Italian patients with gastrointestinal *** A total of 300 consecutive patients with a diagnosis of gastrointestinal malignancy and treated with a fluoropyrimidine-based regimen were included in the analysis and divided into two cohorts:(1)149 patients who started fluoropyrimidines after DPYD testing;and(2)151 patients treated without DPYD *** the patients in cohort A,15%tested only the DPYD2A polymorphism,19%tested four polymorphisms(DPYD2A,HapB3,c.2846A>T,and DPYD13),and 66%tested five polymorphisms including *** Overall,14.8%of patients were found to be carriers of a DPYD variant,the most common being DPYD6(12.1%).Patients in cohort A reported≥G3 toxicities(P=0.00098),particularly fewer nonhematological toxicities(P=0.0028)compared with cohort B,whereas there was no statistically significant difference between the two cohorts in hematological toxicities(P=0.6944).Significantly fewer chemotherapy dose reductions(P=0.00002)were observed in cohort A compared to cohort B,whereas there was no statistically significant differences in chemotherapy *** Although this study had a limited sample size,it provides additional information on the prevalence of DPYD polymorphisms in the Italian population and highlights the role of pharmacogenetic testing to prevent severe toxicity.

关键词： Dihydropyrimidine dehydrogenase DPYD polymorphisms Fluoropyrimidine Caucasian population gastrointestinal cancers

Current and future perspectives in the management and treatment of colorectal cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical oncology 2025年第2期16卷 9-17页

作者： Sigfredo E Romero-Zoghbi Evita Krumina Fernando López-Campos Felipe Couñago department of Radiation oncology GenesisCare Talavera de la ReinaToledo 45600Spain department of Radiation oncology GenesisCare GuadalajaraGuadalajara 19004Spain department of Radiation oncology Hospital Universitario Ramón Y CajalMadrid 28034Spain department of Radiation oncology GenesisCare-Hospital Universitario Vithas Madrid La MilagrosaMadrid 28010Spain

In this editorial,we reviewed the article by Fadlallah et al that was recently published in the World Journal of Clinical *** article provided a comprehensive and in-depth view of the management and treatment of colorectal cancer(CRC),one of the leading causes of cancer-related morbidity and mortality *** article analyzed the therapeutic modalities and their sequencing,focusing on total neoadjuvant therapy for locally advanced rectal *** highlighted the role of immunotherapy in tumors with high microsatellite instability or deficient mismatch repair,addressing recent advances that have improved prognosis and therapeutic response in localized and metastatic *** in surgical techniques,advanced radiotherapy,and systemic agents targeting specific mutational profiles are also discussed,reflecting on how they revolutionized clinical *** tumor DNA has emerged as a promising tool for detecting minimal residual disease,prognosis,and therapeutic monitoring,solidifying its role in precision *** review emphasized the importance of technological and therapeutic advancements in improving clinical outcomes and personalizing CRC treatment.

关键词： Colorectal cancer Metastatic colorectal cancer Total neoadjuvant therapy Chemoradiotherapy Colon surgery Rectal surgery Chemotherapy Immunotherapy

Lipid levels and insulin resistance markers in patients with colorectal cancer:Propensity score matching analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第1期17卷 130-142页

作者： Ren-Hao Hu Dong-Yi Yan Ke-Hui Zhang Di Zhang Xi-Mao Cui Xiao-Hua Jiang Shun Zhang department of gastrointestinal Surgery Shanghai East HospitalSchool of MedicineTongji UniversityShanghai 200120China School of Medicine Tongji UniversityShanghai 200092China department of Emergency Medicine Shanghai East HospitalSchool of MedicineTongji UniversityShanghai 200120China

BACKGROUND Colorectal cancer(CRC)is a prevalent malignant neoplasm characterized by subtle early *** To investigate the correlation among serum lipid profiles,the triglyceride-glucose(TyG)index,and the atherosclerotic index(AI)in patients with ***,it explored the clinical diagnostic utility of combining serum lipids with cancer antigens in the context of *** A retrospective analysis encompassed 277 patients with CRC and 1034 healthy *** Following propensity score matching,patients with CRC exhibited significantly reduced levels of serum triglyceride(TG),total cholesterol(TC),high-density lipoprotein cholesterol,and low-density lipoprotein cholesterol(LDL-C),as well as a diminished TyG ***,they displayed elevated AI levels compared to their healthy *** in advanced stages exhibited lower serum levels of TG,TC,and LDL-C compared to those in early *** with positive lymph node metastasis demonstrated reduced levels of TG,LDL-C,and the TyG *** operating characteristic analysis revealed that the combination of the TyG index,carcinoembryonic antigen,and carbohydrate antigen 19-9 yielded the highest positive prediction rate for CRC at 75.3%.CONCLUSION Preoperative serum lipid profiles exhibit a robust association with patients with *** concurrent assessment of multiple serum lipids and cancer antigens effectively enhances the diagnostic accuracy for CRC.

关键词： Colorectal cancer Serum lipids Triglyceride-glucose index Atherosclerotic index Diagnostic marker

Significance of pathological positive superior mesenteric/portal venous invasion in pancreatic cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2016年第6期15卷 572-578页

作者： Mallika Tewari Hepato Pancreatico Biliary and gastrointestinal Division Department of Surgical OncologyInstitute of Medical SciencesBanaras Hindu University

BACKGROUND： Pancreaticoduodenectomy with superior mesenteric/portal venous resection for pancreatic ductal ad- enocarcinoma （PDAC） is frequently performed with no added morbidity or mortality in case of tumor abutment to the superior mesenteric or portal vein so as to obtain a margin negative resection. True histopathological portal vein invasion is found only in a small subset of such patients. The aim of this review aimed to discuss the significance of histopathological venous invasion in *** SOURCES： For this review available data was searched from PubMed and analyzed. No randomized trials have been published on this topic. RESULTS： Existing data on prognostic factors in histopathological venous invasion by PDAC are limited and recent studies indicate worse survival in this subgroup of patients. In addition, venous invasion in PDAC has been associated with large tumors, involved lymph nodes, perineural invasion and R1 resection. The survival of patients with portal venous re- section but without histologic venous invasion is reportedly better than those with histopathological venous invasion; though conflicting studies do exist on the subject. Some studies also relate the depth of venous invasion to prognosis after surgical resection of PDAC. CONCLUSIONS： Frank/＇histopathological＇ invasion of superior mesenteric/portal venous and R1 resection indicate a very poor survival. Such patients may be given the opportunity of benefit of neoadjuvant treatment.

关键词： pancreatic ductal adenocarcinoma superior mesenteric/portal venous invasion histologic venous invasion prognosis survival

Use of liquid biopsies in gastrointestinal cancers

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2021年第9期13卷 1210-1212页

作者： Hussein H Khachfe department of gastrointestinal surgical oncology University of PittsburghPittsburghPA 15232United States

The use of liquid biopsies is a relatively new tool in diagnosis and management of gastrointestinal cancers and is actively being *** biopsies have become extremely popular in cholangiocarcinoma and pancreatic cancer *** more prospective trials using this tool for early diagnosis,liquid biopsies may become an important part of cancer management.

关键词： Liquid biopsy gastrointestinal cancer Cholangiocarcinoma Pancreatic cancer

TRIPLET combined with microwave ablation:A novel treatment for advanced hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第1期17卷 10-12页

作者： Fei-Yu Zhao Guo-Wei Si Nian-Song Qian department of Thoracic oncology Respiratory and Critical Care MedicineThe Eighth Medical Center of People’s Liberation Army General HospitalBeijing 100853China department of Gastroenterology Fourth Medical CentreGeneral Hospital of the People's Liberation ArmyBeijing 100142China Senior department of Thoracic oncology Respiratory and Critical Care MedicineThe Eighth Medical Center of People’s Liberation Army General HospitalBeijing 100091China

This editorial comments on a study by Zuo et *** focus is on the efficacy of he-patic arterial infusion chemotherapy combined with camrelizumab and apatinib(the TRIPLET regimen),alongside microwave ablation therapy,in treating advanced hepatocellular carcinoma(HCC).The potential application of this combination therapy for patients with advanced HCC is evaluated.

关键词： Microwave ablation Hepatic arterial infusion chemotherapy Apatinib Camrelizumab Hepatocellular carcinoma

Breakthrough therapy for peritoneal carcinomatosis of gastric cancer:Intraperitoneal chemotherapy with taxanes

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2015年第11期7卷 285-291页

作者： Hironori Yamaguchi Joji Kitayama Hironori Ishigami Shinsuke Kazama Hiroaki Nozawa Kazushige Kawai Keisuke Hata Tomomichi Kiyomatsu Toshiaki Tanaka Junichiro Tanaka Takeshi Nishikawa Kensuke Otani Koji Yasuda Soichiro Ishihara Eiji Sunami Toshiaki Watanabe department of surgical oncology the University of Tokyo

The effect of chemotherapy on peritoneal carcinomatosis(PC) of gastric cancer remains ***,the intraperitoneal(IP) administration of taxanes [e.g.,paclitaxel(PTX) and docetaxel(DOC)] during the perioperative period has shown promising ***,we summarized the rationale and methodology for using IP chemotherapy with taxanes and reviewed the clinical *** administered taxanes remain in the IP space at an extremely high concentration for 48-72 *** drug directly infiltrates peritoneal metastatic nodules from the surface and then produces antitumor effects,making it ideal for IP *** are two types of perioperative IP chemotherapy with taxanes: neoadjuvant intraperitoneal and systemic chemotherapy and sequential perioperative intraperitoneal chemotherapy(SPIC).In SPIC,patients receive neoadjuvant IP chemotherapy and the same regimen of IP chemotherapy after cytoreductive surgery(CRS) until disease ***,a taxane dissolved in 500-1000 m L of saline at ordinary temperature is administered through an IP access port on an outpatient *** to phase Ⅰ?studies,the recommended doses(RD) are as follows: IP DOC,45-60 mg/m2; IP PTX [without intravenous(IV) PTX],80 mg/m2; and IP PTX(with IV PTX),20 mg/*** Ⅱ studies have reported a median survival time of 14.4-24.6 mo with a 1-year overall survival of 67%-78%.A phase Ⅲ study comparing S-1 in combination with IP and IV PTX to S-1 with IV cisplatin started in *** prognosis of patients who underwent CRS was better than that of those who did not; however,this was partly due to selection *** several phase Ⅱ studies have shown promising results,a randomized controlled study is needed to validate the effectiveness of IP chemotherapy with taxanes for PC of gastric cancer.

关键词： Taxane Paclitaxel Docetaxel Carcinoma Gastric canc

Precision surgical approach with lymph-node dissection in early gastric cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2019年第14期25卷 1640-1652页

作者： Shinichi Kinami Naohiko Nakamura Yasuto Tomita Takashi Miyata Hideto Fujita Nobuhiko Ueda Takeo Kosaka department of surgical oncology Kanazawa Medical University

The gravest prognostic factor in early gastric cancer is lymph-node metastasis,with an incidence of about 10% overall. About two-thirds of early gastric cancer patients can be diagnosed as node-negative prior to treatment based on clinicpathological data. Thus, the tumor can be resected by endoscopic submucosal dissection. In the remaining third, surgical resection is necessary because of the possibility of nodal metastasis. Nevertheless, almost all patients can be cured by gastrectomy with D1+ lymph-node dissection. Laparoscopic or robotic gastrectomy has become widespread in East Asia because perioperative and oncological safety are similar to open surgery. However, after D1+ gastrectomy,functional symptoms may still result. Physicians must strive to minimize postgastrectomy symptoms and optimize long-term quality of life after this *** on the location and size of the primary lesion, preservation of the pylorus or cardia should be considered. In addition, the extent of lymph-node dissection can be individualized, and significant gastric-volume preservation can be achieved if sentinel node biopsy is used to distinguish node-negative *** the surgical treatment for early gastric cancer may be less radical than in the past, the operative method itself seems to be still in transition.

关键词： Stomach neoplasms surgery Gastrectomy methods Recovery of function Sentinel lymph node surgery Gastric cancer